摘要
带量采购政策旨在降低民众医疗费用,提升民众用药水平,是我国当前医改的重要组成部分。本文以降血脂药为例,分析我国药品市场在带量采购等医改新政下的变化特征,对比中美降血脂药物的产品价格、市场份额等特征,发现我国降血脂药物市场中,已过专利保护期的原研药物市场份额长期居高不下,未出现国外药品市场的"专利悬崖"现象①,并分析其内在原因。进一步,结合我国一致性评价、带量采购等政策的具体内容和实施结果,对未来市场进行预判,认为未来仿制药市场竞争将以质量和价格为主线,价格将回归合理,市场集中度可能会迅速上升。为确保政策有效实施,国家监管部门需进一步加强药物临床疗效等质量监管体系建设,同时运用政策引导、鼓励企业加大创新研发力度。
This article analyzes the changing characteristics and future trends of the hypolipidemic drug market in China under the new policy of medical reform such as volume purchase.This article compares the product price,market share,and other characteristics of Chinese and American lipid-lowering drugs,and finds that in the Chinese lipid-lowering drug market,the original drug market share that has passed the patent protection period has remained high for a long time,and there is no"patent cliff"in the foreign drug market And analyze the underlying causes.Further,this article takes into account the specific content and implementation results of policies such as China’s consistency assessment and quantity procurement,and makes a prediction of the future market.This article believes that in the future,the competition in the generic drug market will focus on quality and price,prices will return to reasonable,and market concentration may rise rapidly.Finally,this article proposes that in order to ensure effective implementation of policies and achieve predetermined results,national regulatory authorities need to pay more attention to strengthening the quality supervision system construction of clinical efficacy of drugs,while using policies to guide and encourage enterprises to increase innovation and research and development efforts.
出处
《价格理论与实践》
北大核心
2019年第12期19-22,111,共5页
Price:Theory & Practice
基金
上海交通大学行业研究院制药团队研究成果之一,上海交通大学行业研究院研究资助,项目批准号:ZYHY2019A01.
作者简介
通讯作者:张洲驰。
